A leading pharmaceutical expert has cautioned that weight-loss injections such as Mounjaro may lead to life-threatening bowel perforations... This warning comes after an inquest into the death of a 73-year-old grandmother revealed how these drugs can cause fatal intestinal tears.
Penny Ward's warning on gut pressure and bowel tears
Penny Ward, a pharmaceutical expert from King's College London, explains that GLP-1 receptor agonists—the class of drugs including Mounjaro and Wegovy—function by slowing the movement of the gastrointestinal tract. According to the report, this slowing effect can create a backlog of waste products, which in turn exerts dangerous pressure on the sensitive lining of the bowel.
This physiological pressure increases the likelihood of a perforation, or a hole, forming in the intestine. Ms. Ward emphasizes that individuals with pre-existing conditions that weaken the bowel lining, such as diverticular disease, are at a heightened risk. When such a tear occurs, bacteria and faecal matter can leak into the abdominal cavity, leading to faecal peritonitis and sepsis, a condition that can kill roughly half of affected patients within hours.
The fatal dose increase from 7.5mg to 10mg for Caroline Savage
The danger of these medications was highlighted by the death of Caroline Savage, a 73-year-old woman from Norfolk. Ms. Savage began using Mounjaro in July 2024 and successfully reduced her weight from 128 kilograms to 114 kilograms by October. However, as reported, her condition deteriorated after she followed medical advice to increase her dosage from 7.5 milligrams to 10 milligrams.
Following the dose escalation, Ms. Savage experienced sudden and constant abdominal pain. While she was treated at the Norfolk and Norwich Hospital, doctors ruled out pancreatitis and discharged her. she was found unresponsive by her husband shortly after returning home.. A similar tragedy occurred in October 2024 with Susan McGowan, a 58-year-old Scottish nurse who died from organ failure and septic shock after receiving only two injections of tirzepatide.
The risk profile for 1.6 million UK users of GLP-1 agonists
The rise of tirzepatide and semaglutide has seen these medications become some of the most sought-after treatments globally, with 1.6 million adults in the UK currently using them. The UK government has further expanded access by approving these drugs for NHS use to treat obesity and assisting those with obesity-related disabilities in returning to the workforce.
While experts agree that GLP-1 injections are safe and effective for the vast majority of the population, the scale of adoption increases the statistical likelihood of rare, devastating side effects. The broader trend of utilizing diabetes medications for weight loss has outpaced the official documentation of rare complications, leaving some patients and prescribers unaware of the specific red flags associated with bowel health.
Why Norfolk and Norwich Hospital missed the perforation
A critical point of contention in the inquest into Caroline Savage's death is the diagnostic process. The report indicates that detailed imaging, specifically an X-ray or CT scan, might have detected the bowel perforation before Ms. Savage was discharged from the Norfolk and Norwich Hospital, potentially saving her life.
This raises urgent questions about why bowel perforation is not officially listed as a side effect for these blockbuster jabs and whether clinicians are sufficiently trained to distinguish between common GLP-1 side effects—like nausea and vomiting—and the "red flag" of sudden, severe abdominal pain. It remains unclear if pharmaceutical manufacturers have been notified of these specific clusters of fatalities or if updated guidance for NHS prescribers is forthcoming.
Comments 0